Business
Zhongchao Inc. Joined Hands with Professional Non-Profit Organizations and 9 Leading Pharma Companies to Carry Out Multi-Year Online Education Project on Diagnosis and Treatment of Primary Liver Cancer
SHANGHAI, July 23, 2020 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering patient
About this update from Zhongchao Inc.
[{"type":"text","content":"SHANGHAI, July 23, 2020 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) (\"Zhongchao\" or the \"Company\"), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced that it joined hands with China Health Promotion Association (\"CHPA\"), the Liver Cancer Committee of Chinese Anti-Cancer Association (\"CACA\"), and 9 leading pharmaceutical companies, including Roche (China) Co., Ltd., Bayer (China) Limited, Eisai China Inc., Merck (China) Ltd., Jiangsu Hengrui Medicine Co., Ltd., Innovent Biologics, Inc., Junshi Biosciences, Gilead Sciences Shanghai Pharmaceutical Technology Co., Ltd., and BeiGene, Ltd., to carry out a multi-year online education project on the diagnosis and treatment of primary liver cancer (the \"Project\"). \nThe Project aims to promote and implement \"the Specifications for the Diagnosis and Treatment of Primary Liver Cancer in China (2019 Edition)\" (the \"Specifications\"), a national guideline promulgated by the National Health Commission (the \"NHC\"), and is available on our MDMOOC platform at www.MDMOOC.org. \nThe Project is chaired by Professor Jia Fan, an academician of Chinese Academy of Sciences and the President of Zhongshan Affiliated Hospital of Fudan University, with instructors including 29 leading experts from 13 AAA-Grade Hospitals in China. The Project covers topics in primary liver cancer including but not limited to screening, diagnosis, staging, treatment and patient management. \nWeiguang Yang, Chairman and Chief Executive Officer of Zhongchao, commented, \"The Specifications echo the Healthy China 2030 Initiative, which outlines the Chinese government's endeavors to achieve health targets aligned with the United Nations' sustainable development goals. Through close cooperation among CHPA, CACA, Zhongchao, and these leading pharmaceutical companies, the Project offers participants the opportunity to stay abreast of the latest advances in liver cancer. We believe the project is of great significance to further improve the rate of early diagnosis and treatment of liver cancer and the survival rate of liver cancer patients in China.\"\nThe Project will be carried out in multi-year, multi-phase. Since the Project's launch in March 2020, a total of over 145,000 liver surgeons, oncologists, hepatolog...